Eli Lilly company headlines, earnings, strategy, leadership, and market-moving business updates.
Market data may be delayed. For informational purposes only. Not investment advice.
In comments covered from its earnings call, Eli Lilly said revenue rose sharply on strong demand for Mounjaro and Zepbound, prompting an increase to its full-year guidance.
THE APEX TIMES
THE APEX TIMES
The company said it has filed six lawsuits targeting sellers it says are offering unofficial versions of its next-generation triple-therapy obesity drug, as it prepares an approval-related filing.
THE APEX TIMES
A recent market-focused note highlighted Eli Lilly, calling the stock close to a new “buy point” amid strength in the broader equity rally.
THE APEX TIMES
The drugmaker says newly targeted sellers are offering products that are unverified and unapproved, and it is stepping up legal action aimed at limiting off-channel distribution of retatrutide.
THE APEX TIMES
The company filed six additional lawsuits targeting U.S. entities it says are marketing black-market retatrutide through online platforms and payment channels, urging regulators and intermediaries to intervene.
THE APEX TIMES
Absci Corporation reported a wider second-quarter net loss while Eli Lilly invested $40 million tied to its ABS-201 program, helping the stock rebound on Tuesday.
THE APEX TIMES
A recent market take argues that Eli Lilly may represent the cleaner long-term bet as competition intensifies in GLP-1 obesity and diabetes medicines, while Novo Nordisk is portrayed as working to close gaps in a fast-moving commercial and clinical landscape.
THE APEX TIMES
A market report highlights momentum for Lilly’s obesity pipeline and points to how a new market opportunity could speed progress toward oral treatments for weight management.
THE APEX TIMES
The company said the United Kingdom will be its first international market for its weight-loss pill, a step that could broaden access in a closely watched obesity-drug race.
